Christine Reynolds

514 total citations
15 papers, 420 citations indexed

About

Christine Reynolds is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Pharmacology. According to data from OpenAlex, Christine Reynolds has authored 15 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 5 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Christine Reynolds's work include Pharmacogenetics and Drug Metabolism (5 papers), Analytical Methods in Pharmaceuticals (3 papers) and Blood Pressure and Hypertension Studies (2 papers). Christine Reynolds is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Analytical Methods in Pharmaceuticals (3 papers) and Blood Pressure and Hypertension Studies (2 papers). Christine Reynolds collaborates with scholars based in United States, Switzerland and France. Christine Reynolds's co-authors include Christiane Rordorf, Dan Howard, Sujata Vaidyanathan, Marie‐Noëlle Bizot, H. A. Dieterich, William P. Dole, Gian Camenisch, John M. Kovarik, Kenneth C. Lasseter and Stacy C. Dilzer and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and Drug Metabolism and Disposition.

In The Last Decade

Christine Reynolds

15 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christine Reynolds United States 11 105 92 87 87 72 15 420
Michael J. Knauer Canada 12 78 0.7× 191 2.1× 47 0.5× 56 0.6× 101 1.4× 25 603
Klaus Moerike Germany 5 146 1.4× 92 1.0× 76 0.9× 66 0.8× 124 1.7× 6 582
Jin Ah Jung South Korea 11 58 0.6× 100 1.1× 72 0.8× 41 0.5× 65 0.9× 49 409
William J. Jusko United States 13 38 0.4× 90 1.0× 46 0.5× 92 1.1× 86 1.2× 17 607
Ching‐Ming Yeh United States 13 271 2.6× 55 0.6× 45 0.5× 224 2.6× 43 0.6× 18 466
Gurusamy Umamaheswaran India 13 78 0.7× 85 0.9× 41 0.5× 133 1.5× 33 0.5× 30 411
Nihal El Rouby United States 12 83 0.8× 51 0.6× 48 0.6× 54 0.6× 105 1.5× 24 617
Hyewon Chung South Korea 16 46 0.4× 64 0.7× 50 0.6× 65 0.7× 57 0.8× 45 592
Mariana Rodrigues Botton Brazil 14 78 0.7× 100 1.1× 52 0.6× 70 0.8× 127 1.8× 36 592
Sjoerd P. van Marle Switzerland 8 134 1.3× 76 0.8× 35 0.4× 69 0.8× 38 0.5× 8 533

Countries citing papers authored by Christine Reynolds

Since Specialization
Citations

This map shows the geographic impact of Christine Reynolds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Reynolds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Reynolds more than expected).

Fields of papers citing papers by Christine Reynolds

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Reynolds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Reynolds. The network helps show where Christine Reynolds may publish in the future.

Co-authorship network of co-authors of Christine Reynolds

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Reynolds. A scholar is included among the top collaborators of Christine Reynolds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Reynolds. Christine Reynolds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Yang, Wen‐Yuan, et al.. (2021). A molecular and serological survey in Taiwan to determine the true risk of babesiosis in dogs not receiving regular tick prevention. Veterinary Parasitology Regional Studies and Reports. 27. 100670–100670. 4 indexed citations
2.
Lindgren, S., et al.. (2018). Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects. Clinical Pharmacology in Drug Development. 7(8). 829–836. 6 indexed citations
3.
Gan, Lu, Xuemin Jiang, Anisha E. Mendonza, et al.. (2015). Pharmacokinetic drug–drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel‐ethinyl estradiol in healthy subjects. Clinical Pharmacology in Drug Development. 5(1). 27–39. 19 indexed citations
4.
Sunkara, Gangadhar, Xuemin Jiang, Christine Reynolds, et al.. (2014). Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects. Clinical Pharmacology in Drug Development. 3(6). 487–492. 8 indexed citations
5.
He, Yanling, Kenneth Kulmatycki, Yiming Zhang, et al.. (2013). Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. International Journal of Clinical Pharmacology and Therapeutics. 51(9). 693–703. 21 indexed citations
6.
Kagan, Mark, et al.. (2012). Metabolism and Pharmacokinetics of Indacaterol in Humans. Drug Metabolism and Disposition. 40(9). 1712–1722. 19 indexed citations
7.
Pascoe, Steven, Christine Reynolds, Warren Pleskow, et al.. (2011). Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. International Journal of Clinical Pharmacology and Therapeutics. 49(2). 153–161. 10 indexed citations
8.
Rivière, Gilles, et al.. (2011). Bioequivalence of a Novel Omalizumab Solution for Injection Compared with the Standard Lyophilized Powder Formulation. Journal of Bioequivalence & Bioavailability. 3(6). 21 indexed citations
9.
Abdulla, Salim, Mbaraka Amuri, Abdunoor M. Kabanywanyi, et al.. (2010). Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malaria Journal. 9(1). 253–253. 21 indexed citations
10.
Vaidyanathan, Sujata, Gian Camenisch, Christine Reynolds, et al.. (2008). Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren. The Journal of Clinical Pharmacology. 48(11). 1323–1338. 87 indexed citations
11.
Vaidyanathan, Sujata, Christine Reynolds, Ching‐Ming Yeh, et al.. (2007). Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects. The Journal of Clinical Pharmacology. 47(4). 453–460. 43 indexed citations
12.
Sunkara, Gangadhar, et al.. (2007). Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Current Medical Research and Opinion. 23(3). 631–640. 21 indexed citations
13.
Scott, Graham, Christine Reynolds, Slavica Milosavljev, et al.. (2004). Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib. Clinical Pharmacokinetics. 43(5). 341–348. 10 indexed citations
14.
Scott, Graham, Christiane Rordorf, Christine Reynolds, et al.. (2004). Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid. Clinical Pharmacokinetics. 43(7). 467–478. 55 indexed citations
15.
Kovarik, John M., et al.. (2001). Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment. Clinical Pharmacology & Therapeutics. 70(5). 425–430. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Knauer Breakdown of academic impact, for papers by Klaus Moerike Breakdown of academic impact, for papers by Jin Ah Jung Breakdown of academic impact, for papers by William J. Jusko Breakdown of academic impact, for papers by Ching‐Ming Yeh Breakdown of academic impact, for papers by Gurusamy Umamaheswaran Breakdown of academic impact, for papers by Nihal El Rouby Breakdown of academic impact, for papers by Hyewon Chung Breakdown of academic impact, for papers by Mariana Rodrigues Botton Breakdown of academic impact, for papers by Sjoerd P. van Marle
Rankless by CCL
2026